Orthocell (ASX:OCC): What Does US FDA Clearance for PearlBone Mean?

Sonal Goyal

03 November 2026 06:40 PM AEDT

Orthocell (ASX:OCC): What Does US FDA Clearance for PearlBone Mean?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

• Marine Biomedical has received US FDA 510(k) clearance for PearlBone™, an innovative marine-derived bone graft substitute made from sustainably sourced pearl shell from Western Australia's Kimberley region.

• Orthocell holds a 12% Equity interest in Marine Biomedical following a strategic Investment finalised in January 2026, and has secured a first right of refusal over global distribution rights for PearlBone and future bone repair products.

• FDA clearance enables PearlBone to be marketed in the United States for its cleared indications, representing a significant milestone in the product's commercialisation pathway.

• Marine Biomedical is progressing Manufacturing readiness and market development activities ahead of a planned US market introduction of PearlBone.

Orthocell Limited (ASX:OCC), a regenerative medicine company focused on products for bone and soft tissue repair, has announced that its strategic partner Marine Biomedical Pty Ltd has received US Food and Drug Administration (FDA) 510(k) clearance for PearlBone™. The clearance enables Marine Biomedical to market PearlBone in the United States for its cleared indications and represents a meaningful step forward for the product's commercialisation, with potential implications for Orthocell's own portfolio and distribution capabilities.

What is PearlBone and Why It Matters

PearlBone is a next-generation bone substitute developed using sustainably sourced pearl shell from the Kimberley region of Western Australia. The product harnesses the natural properties of nacre — the biomineralised structure found in pearl shell — to support bone repair and regeneration. Nacre has been the subject of scientific investigation for its potential compatibility with human tissue, and PearlBone is designed to offer surgeons a biologically advanced alternative in bone repair procedures across orthopaedic, trauma, and reconstructive surgery applications.

The FDA 510(k) clearance pathway confirms that PearlBone is substantially equivalent to a legally marketed predicate device, allowing it to be marketed and sold in the United States without requiring a premarket approval — a significant regulatory efficiency for novel biomaterials. PearlBone is manufactured at Marine Biomedical's purpose-built Facility in Broome, Western Australia, supporting the development of advanced biomedical manufacturing capability in regional Australia.

Orthocell's Strategic Investment and Distribution Rights

Orthocell finalised its strategic investment in Marine Biomedical in January 2026, increasing its equity interest to 12% for a total investment amount. Alongside the equity stake, Orthocell secured a first right of refusal over global distribution rights for PearlBone and future bone repair and regeneration products developed by Marine Biomedical. This contractual right, if exercised, could enable Orthocell to Leverage its existing US surgeon relationships, established distributor network, and commercial infrastructure to support PearlBone's introduction to the market.

The investment reflects Orthocell's stated strategy of broadening its portfolio of biologically driven regenerative medicine products across bone, nerve, and tendon repair. Orthocell Chair John Van Der Wielen noted that achieving FDA clearance is a significant step toward unlocking the commercial opportunity and described PearlBone as having considerable potential in the global bone repair and regeneration market.

Commercialisation Progress and Market Opportunity

Marine Biomedical is actively progressing commercial readiness activities ahead of the planned US market launch of PearlBone, including manufacturing readiness, market development initiatives, and engagement with potential commercial and clinical partners. The clearance follows years of scientific development, preclinical evaluation, manufacturing validation, and regulatory preparation, which Marine Biomedical has worked through ahead of its US entry.

The global bone repair and regeneration market is considered a substantial opportunity by industry participants, driven by increasing rates of orthopaedic procedures associated with an ageing global population and advances in surgical techniques. For Orthocell, PearlBone represents an opportunity to expand beyond its established nerve and tendon repair portfolio, adding a bone regeneration dimension to its biologically driven product suite. The exercise of Orthocell's first right of refusal remains subject to the negotiation and agreement of definitive commercial arrangements with Marine Biomedical.

Key Insights

The FDA 510(k) clearance for PearlBone marks a significant de-risking milestone for Marine Biomedical and a potentially value-accretive development for Orthocell's equity stake. The first right of refusal over global distribution rights gives Orthocell optionality to leverage its existing US commercial infrastructure without committing prematurely to distribution arrangements before market readiness has been demonstrated.

Observers may monitor the progress of Marine Biomedical's commercial readiness activities and any subsequent announcements regarding the exercise of Orthocell's distribution rights. The success of PearlBone in the US market could have implications for how the bone regeneration component of Orthocell's portfolio develops over the medium term.

FAQs

Q: What is Orthocell Limited and what products does it sell?

A: Orthocell Limited (ASX:OCC) is a Perth-based regenerative medicine company focused on products for bone, nerve, and tendon repair. Its portfolio includes CelGro collagen medical devices for dental and orthopaedic applications, Remplir for peripheral nerve reconstruction, and Striate+ for dental guided bone regeneration.

Q: What is PearlBone and how is it different from conventional bone grafts?

A: PearlBone is a marine-derived bone graft substitute made from sustainably sourced pearl shell. Its active component is nacre, the biomineralised layer of the shell, which is being developed to support bone repair and regeneration as a biologically advanced alternative to existing bone graft materials.

Q: What does the FDA 510(k) clearance mean for PearlBone?

A: FDA 510(k) clearance means that PearlBone can be legally marketed and sold in the United States for its cleared indications. It confirms the product is substantially equivalent to a legally marketed predicate device, a key regulatory step in the commercialisation of medical devices in the US market.

Q: What is Orthocell's financial relationship with Marine Biomedical?

A: Orthocell holds a 12% equity interest in Marine Biomedical following a strategic investment finalised in January 2026. Alongside this equity stake, Orthocell holds a first right of refusal over global distribution rights for PearlBone and future bone repair and regeneration products.

Q: Will Orthocell distribute PearlBone in the United States?

A: Orthocell has a first right of refusal over global distribution rights for PearlBone, but any distribution arrangement would be subject to the exercise of that contractual right and the agreement of definitive commercial terms with Marine Biomedical.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.